Apothecon Pharmaceuticals

Based in India, Apothecon Pharmaceuticals specializes in the development and production of active pharmaceutical ingredients (APIs) and complex formulations, focusing on therapeutic areas like oncology and central nervous system disorders. Apothecon Pharmaceuticals, founded in 2007 and headquartered in Gujarat, India, develops niche APIs and complex formulations. The company has engaged in one investment deal, with its most recent funding round, a Growth round of USD 270. 00 mn, led by Everstone Capital Partners in April 2026.

The founder’s history is not documented. Apothecon Pharmaceuticals Pvt. Ltd. specializes in the development and production of niche active pharmaceutical ingredients (APIs), peptides, and complex formulations, catering to a diverse range of therapeutic areas, including oncology, central nervous system disorders, and rare diseases.

The company’s product offerings include finished dosage forms (FDFs) such as oral solids, injectables, and nasal sprays, designed with therapeutic precision to enhance patient compliance and efficacy. Apothecon focuses on specialized molecules like iron complexes and chiral APIs, ensuring high-quality production standards upheld by USFDA, UK MHRA, and WHO-GMP certifications. The company distributes its products across over 100 countries, engaging with a wide client base that includes healthcare providers, pharmaceutical companies, and distributors, ultimately aiming to improve patient outcomes globally. Apothecon Pharmaceuticals generates revenue through a structured business model that encompasses both business-to-business and direct-to-consumer transactions.

The company primarily operates on a contract manufacturing basis, partnering with pharmaceutical firms to provide tailored API and FDF solutions. These partnerships often involve technology transfer and commercial production agreements, facilitating the scale-up of specialized products. Apothecon's pricing plans are competitive, reflecting the complexity and quality of its offerings, which include flagship products such as Carmustine injections and Rilpivirine tablets. The company leverages strategic collaborations and distribution channels to ensure its products are accessible in various international markets, allowing it to maintain an effective revenue stream while fulfilling the healthcare needs of patients and professionals alike.

In April 2026, Everstone Group invested USD 270. 00 mn in Apothecon Pharmaceuticals to support its growth strategies. The company plans to develop and launch new products in the oncology segment, enhancing its portfolio by 2027. Apothecon is also targeting expansion into European markets, focusing on countries such as Germany and France, with an anticipated entry by late 2026.

The recent funding will be utilized to support these initiatives and further develop their capabilities in manufacturing and distribution.